findmyKOL

Catherine Tang

Basic profile

Stony Brook University

ORCIDNPI
RegionBoston, MA · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Catherine Tang is an Endocrinology/Metabolic physician affiliated with Stony Brook University. OpenAlex indexes 18 publications with 1,376 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
18publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,376citations

Total citations across indexed works.

13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

330 Brookline Ave
Gryzmish 6
Boston, MA 022155400

Telephone

617-667-9344

Provider last certified this registry record 27 Feb 2020.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    97.1%
    Other drugs affecting bone structure and mineralization85.2%
    Romosozumab-aqqg100%
    Part B, office-administered12 patients
    RANK Ligand Inhibitor11.6%
    Denosumab100%
    Part B, office-administered20 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    1.7%
    Insulin Analog0.7%
    Lantus Solostar59%Humalog Kwikpen U-10018%Novolog Flexpen13%Insulin Lispro Kwikpen U-10010%
    Part D<11 patients
    GLP-1 receptor agonist0.6%
    Mounjaro41%Ozempic30%Trulicity28%
    Part D<11 patients

    + 4 more classes in this area

  • Hormonal (systemic)

    0.9%
    l-Thyroxine0.6%
    Levothyroxine Sodium76%Synthroid24%
    Part D<11 patients
    Thyroid Hormone Synthesis Inhibitor0.2%
    Methimazole100%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”